Related references
Note: Only part of the references are listed.Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
Myeloid-Derived Suppressor Cells: General Characteristics and Relevance to Clinical Management of Pancreatic Cancer
P. Goedegebuure et al.
CURRENT CANCER DRUG TARGETS (2011)
Potential targets for pancreatic cancer immunotherapeutics
Lindzy F. Dodson et al.
IMMUNOTHERAPY (2011)
FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer
Thierry Conroy et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
Chrystelle Brignone et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
A Phase I Pharmacokinetic and Biological Correlative Study of IMP321, a Novel MHC Class II Agonist, in Patients with Advanced Renal Cell Carcinoma
Chrystelle Brignone et al.
CLINICAL CANCER RESEARCH (2009)
IMP321 (sLAG-3) safety and T cell response potentiation using an influenza vaccine as a model antigen: A single-blind phase I study
Chrystelle Brignone et al.
VACCINE (2007)
Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: A phase III trial of the National Cancer Institute of Canada clinical trials group
Malcolm J. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Increased prevalence of regulatory T cells (Treg) is induced by pancreas adenocarcinorna
Udaya K. Liyanage et al.
JOURNAL OF IMMUNOTHERAPY (2006)
A soluble LAG-3 protein as an immunopotentiator for therapeutic vaccines: Preclinical evaluation of IMP321
Sylvie Fougeray et al.
VACCINE (2006)
A soluble lymphocyte activation gene-3 (sLAG-3) protein as a prognostic factor in human breast cancer expressing estrogen or progesterone receptors
F Triebel et al.
CANCER LETTERS (2006)
The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells
L Maçon-Lemaître et al.
IMMUNOLOGY (2005)
Negative regulation of T cell homeostasisby lymphocyte activation gene-3 (CD223)
CJ Workman et al.
JOURNAL OF IMMUNOLOGY (2005)
CD25(+)CD4(+) regulatory T-cells in cancer
DC Linehan et al.
IMMUNOLOGIC RESEARCH (2005)
The CD4-related molecule, LAG-3 (CD223), regulates the expansion of activated T cells
CJ Workman et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2003)
LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination
F Triebel
TRENDS IN IMMUNOLOGY (2003)
Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma
UK Liyanage et al.
JOURNAL OF IMMUNOLOGY (2002)
A soluble lymphocyte activation gene-3 molecule used as a vaccine adjuvant elicits greater humoral and cellular immune responses to both particulate and soluble antigens
S El Mir et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
